Our Research

At Skin Analytics research is at the very core of everything that we do.

Ever since we were founded we’ve been working with top tier machine learning research groups from the Universities of Oxford, Cambridge and Bristol and Imperial College London.

We’ve also worked with internationally recognised clinicians involved at all stages of the skin cancer pathway, as well as experts in health economics. We have formalised these relationships into our Clinical Advisory Committee, which guides our research and services.

 

Observational Study

We’ve undertaken a study on over 6,000 biopsy confirmed mole images.

The results of this study confirmed that our AI, Deep Ensemble for the Recognition of Malignancy (DERM), is as accurate as a dermatologist. See here for the results.

Pioneering Research

We’ve published the world’s first prospective study for AI and melanoma.

The study was designed by leading clinicians to ensure that results truly represent the efficacy of our solution compared to clinicians in a realistic setting. It was conducted across 7 NHS hospitals, led by the Royal Free London and showed that DERM can diagnose suspected skin cancer with the same accuracy as clinical specialists.

See the full press release here.

Non-melanoma Skin Cancer

With a grant run by the Small Business Research Initiative (SBRI) and funded by the NHS we expanded our focus from melanoma to include non-melanoma skin cancer as well. This research produced stunning results and we’ll follow this up with a research paper with one of our partners soon.

Non-melanoma skin cancers are less dangerous than melanoma, but they are also far more common. The diagnosis and treatment of non melanoma skin cancer places a significant burden on the health care system.

Health Economics

We partnered with Advance Queensland under an Ignite Grant and are conducting a study into the health economic benefits of using DERM to help detect skin cancer in primary care.

With the help of leading researchers at Griffith University we have designed a study to work alongside GP’s to help establish how the use of DERM would affect the rate of biopsies conducted.  We plan to show that the use of AI in primary care can reduce the number of biopsies needed to find skin cancer.

We would like to thank Ignite Queensland, Griffith University and Pioneer Health for their support with our research.

Clinical Advisory Committee

Professor Scott Kitchnener

Professor Scott Kitchnener

Committee Chair. Primary Care Medical Service Director

Scott is a qualified specialist in medical leadership and management (FRACMA), a graduate of the AICD, a specialist public health physician (FAFPHM), while remaining a clinician with specialist standing as a general practitioner in rural practice. He has experience in health and education corporate governance and leadership in the private sector, public sector, higher education sector, international and Australian biotech sectors and in the military. His on-going research and experience have been in addressing health issues of developing nations, rural health and workforce, and particularly preventive approaches to public health challenges. 

Dr Niall Wilson

Dr Niall Wilson

Consultant Dermatologist

Niall qualified in Medicine from the University of Liverpool in 1991. He has been an NHS Consultant Dermatologist since 2000. He has special interests in skin cancer, hyperhidrosis and skin disorders in immunosuppressed patients. He has also been involved with postgraduate education for many years and is currently vice chair of the Specialist Advisory Committee for Dermatology, which oversees Dermatology training in the UK.

Dr Lucy Thomas

Dr Lucy Thomas

Consultant Dermatologist

Lucy is a Consultant Dermatologist at the Phoenix Hospital Group in London.

Professor Chris Hyde

Professor Chris Hyde

Health Economics

Chris is a professor of Public Health and Clinical Epidemiology at Exeter University. He is a School lead for research on test evaluation including systematic reviews, economic models and primary research. He leads the Exeter Test Group and is the diagnostics theme lead for PenCLAHRC. He is part of the Peninsula Technology Assessment Group (PenTAG). He directed the team delivering health technology assessments for national policy-making bodies, particularly NICE, from 2009 until 2015 and continues to support it by being the lead on HTAs of tests and through membership of its steering group. He is a long standing member of NICE’s Diagnositc Advisory Committee and recently joined the National Screening Committee.

Get in Touch

  • This field is for validation purposes and should be left unchanged.